{"OMIM ID": "OMIM:617166", "DISEASE": "Epileptic Encephalopathy, Early Infantile, 47", "RECORD": "Rare disease patients have complex clinical representations. Patients with Epileptic Encephalopathy, Early Infantile, 47 present clinical features that include seizures, developmental delay, and movement disorders. These patients are also at risk for severe intellectual disability, behavioral problems, and epilepsy. The genetic cause of this disease is unknown.\n\nAbout Epilepsy\n\nEpilepsy is a chronic neurological disorder characterized by recurrent seizures. A seizure is a clinical manifestation resulting from. Some special cases also present with cognitive impairment, behavioral problems, and movement disorders. Epilepsy is a common disorder, affecting approximately 1% of the population.\n\nAbout Neurocrine Biosciences\n\nNeurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. The Company in-licenses the global development and commercialization rights to a portfolio of drug candidates for neurological and endocrine diseases and disorders. The Company's lead product candidate is tasimelteon, a melatonin receptor agonist, for the treatment of insomnia. The Company is also developing a. The main symptomatic differences of Epileptic Encephalopathy, Early Infantile, 47 from similar diseases is that the patients present with seizures, developmental delay, and movement disorders. The genetic cause of this disease is unknown.\n\nSource: http://www.neurocrine.com/", "SUMMARY": "Epilepsy/epilepsy.aspx\n\nWhat does this mean?\n\nThanks for your help!\n\n\"Rare disease patients have complex clinical representations. Patients with Epileptic Encephalopathy, Early Infantile, 47"}